RSV Human Viral Challenge Studies


hVIVO is the global leader in conducting human viral challenge studies also recently referred to as Controlled Human Infection Models or CHIM. We have inoculated over 750 subjects in human viral challenge studies for Respiratory Syncytial Virus(RSV) vaccines and treatments. Positive results from an RSV challenge study conducted with hVIVO have led to a large increase in asset valuation and fast track status at the FDA. We will be presenting the data from our RSV pilot challenge study in adults 55-75 years of age on Thursday. More details are available in the link.